We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cost-effectiveness of FDG-PET

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01438164
Recruitment Status : Completed
First Posted : September 21, 2011
Last Update Posted : September 21, 2011
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Condition or disease
Oncologic Patients

Detailed Description:
To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Study Design

Study Type : Observational
Actual Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET
Study Start Date : June 2005
Primary Completion Date : June 2010
Study Completion Date : September 2011
Groups and Cohorts

Group/Cohort
oncologic patients
initial staging


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
500 oncologic patients
Criteria

Inclusion Criteria:

  • Cancer

Exclusion Criteria:

  • Other malignancy
  • Uncontrolled Diabetes
  • Pregnancy
More Information

Responsible Party: Juliano Julio Cerci, Pesquisador executante, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT01438164     History of Changes
Other Study ID Numbers: USP0460/05
First Posted: September 21, 2011    Key Record Dates
Last Update Posted: September 21, 2011
Last Verified: September 2011

Keywords provided by Juliano Julio Cerci, University of Sao Paulo:
FDG-PET
cancer
staging
Evaluate the cost impact in the evaluation of oncologic patients.